Carcinoembryonic antigen (CEA)

Overview

Carcinoembryonic antigen (CEA) is a glycoprotein tumor-associated antigen widely used in oncology as a biomarker and experimental target. It is best known for its clinical association with gastrointestinal malignancies, especially colorectal cancer, but it is also studied across other solid tumors, including gastric, lung, breast, head/neck, melanoma, and prostate Cancers. In biomedical research, CEA is valued both as a measurable circulating marker and as a cell-surface target for diagnostic and therapeutic strategies.

Biologically, CEA is relevant because its expression can reflect tumor burden, disease progression, or treatment response in some settings. It is also used as a target antigen for immunotherapy platforms, including CD3-based bispecific T-cell engagers, where binding to CEA on tumor cells can help redirect cytotoxic T cells toward antigen-specific killing. In parallel, CEA is a major focus of biosensor development because sensitive detection can support early diagnosis and treatment monitoring.

Recent Publications Summary

Recent publications on carcinoembryonic antigen (CEA) largely focused on assay development and diagnostic performance, with multiple platforms designed to improve sensitivity, portability, and signal amplification. A sandwich colorimetric immunoassay using peroxidase-like CuFeS2 nanoclusters coupled with glucose oxidase-labeled AuNP probes achieved a linear range of 0.05–40 ng/mL and a detection limit of 22 pg/mL, while showing acceptable repeatability, 91% signal retention after one month at 4 °C, and consistency with commercial ELISA in preliminary serum testing 42579023Aug. In a related portable format, strain-induced PtCu nanozymes enabled a paper-based smartphone-readout assay with a CEA range of 0.1–50 ng/mL and effective resistance to interference in clinical blood samples 42300353Jun.

Other studies used fluorescence, electrochemiluminescence, and lateral flow strategies to extend CEA detection toward ultra-sensitive and point-of-care use. A turn-on aptasensor based on Ce-UiO-66 as an ultraefficient nanoquencher achieved dual-linear detection from 1–10 ng/mL and 10–100 ng/mL, with a 13.78 pg/mL detection limit and good recovery in diluted serum 42141320May. A CuInS2 quantum dot aerogel boosted electrochemiluminescence by 76-fold relative to individual quantum dots and supported a CEA immunosensor with a 1 pg/mL to 100 ng/mL linear range and 0.34 pg/mL detection limit 42027093Apr. In another label-free photoelectrochemical format, a tandem built-in electric field strategy in a SnS2/ZIS@ZnS heterojunction was triggered after CEA-specific sandwich recognition, leading to enhanced photocurrent and sensitive CEA detection 42018287Apr. For lateral flow testing, a coordination/assembly twin-boosted LFIA using ZIF-8-mediated signal programming and AuNP loading reduced the limit of detection by 25–50-fold versus conventional LFIA in CEA model testing 42289865Jun.

CEA was also incorporated into broader biosensing and diagnostic comparison studies. Terahertz meta-biosensors modified with CEA antibody-conjugated AuNPs showed specific frequency shifts proportional to CEA concentration in mixed tumor-marker samples, and machine-learning classification of transmission spectra supported discrimination among concentrations 42154628May. A head-to-head clinical comparison found that fecal CEA was less diagnostically informative than serum CEA for colorectal cancer detection, with serum CEA showing a significantly higher AUC than fecal measurements obtained with either processing method 41957956Apr.

Beyond direct detection, CEA served as a prognostic variable and therapeutic target in colorectal cancer research. In a retrospective Stage II-III colorectal cancer cohort, CEA ≥5.0 ng/mL was one component of a symptom-tumor-nutrition score that stratified patients into low, mid, and high risk groups; high scores were associated with worse disease-free survival and overall survival, and independently predicted poorer outcomes in multivariable analysis 42527097Jul. Separately, a bispecific T-cell engager targeting CEA was combined with L19-TNF to remodel the tumor microenvironment in colorectal cancer, with immunohistochemistry confirming coexpression of CEA and EDB and the combination producing enhanced tumor cell killing in vitro and complete regression in most animals in vivo 42012522Apr.

What Changes, What Holds

1. High-sensitivity portable immunoassays now broaden CEA measurement more than they redefine its role
METHOD CuFeS2- and PtCu-based formats mainly strengthen the existing biosensor and monitoring use of CEA by pushing detection lower, improving portability, and showing workable serum performance. They do not alter the baseline view of CEA as a measurable circulating marker; instead, they expand the assay toolbox for that established application and suggest better point-of-care feasibility 42579023Aug42300353Jun.

2. Ultra-sensitive optical platforms make CEA detection more practical at very low concentrations
METHOD Aptasensor, electrochemiluminescent, photoelectrochemical, and lateral-flow designs mainly advance how CEA is studied and measured, not what CEA is. The new work supports the established biosensor emphasis by improving sensitivity, amplification, and point-of-care format, while leaving the clinical meaning of CEA unchanged; the terahertz and machine-learning work also fits this measurement-focused extension 42141320May42027093Apr.

3. Serum remains the preferred matrix when CEA is used diagnostically
REINFORCES Fecal CEA underperforming serum CEA sharpens, rather than revises, the established diagnostic hierarchy around this biomarker. The comparison suggests that alternative sample types do not yet rival serum for colorectal cancer detection, which is consistent with the baseline account of CEA as a clinically useful circulating marker and argues against shifting routine diagnostic attention away from serum-based testing 41957956Apr.

4. CEA is gaining support as a prognostic risk variable and a therapeutic target in colorectal cancer
REINFORCES CEA-linked risk stratification and combination immunotherapy both extend the baseline but do not contradict it: CEA is already described as a marker of burden/progression and a target for CD3-based T-cell engagers. The prognostic score suggests added clinical utility in outcome prediction, while the combination study strengthens the case that CEA-targeted immune therapy can be paired with microenvironment modulation for better antitumor activity 42527097Jul42012522Apr.

Overview update candidates: improved assay sensitivity/portability for CEA measurement; serum preferred over fecal CEA for colorectal cancer detection; CEA as a prognostic variable in colorectal cancer risk stratification; combination strategies that enhance CEA-targeted T-cell engager therapy.